This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Immune Response in Peripheral Blood of Patients With Colon Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Arizona Identifier:
First received: May 9, 2009
Last updated: December 2, 2015
Last verified: August 2012

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.

PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.

Condition Intervention
Colorectal Cancer Other: immunoenzyme technique Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract

Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) [ Time Frame: 3 months ]

Enrollment: 67
Study Start Date: July 2004
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Detailed Description:


  • Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.

OUTLINE: This is an open-label study.

Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.

PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
colon cancer


  • Diagnosis of colon cancer


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00900432

United States, Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States, 85724-5024
Sponsors and Collaborators
University of Arizona
National Cancer Institute (NCI)
Study Chair: Michael Demeure, MD University of Arizona
  More Information

Responsible Party: University of Arizona Identifier: NCT00900432     History of Changes
Other Study ID Numbers: 04-0331-01
P50CA095060 ( U.S. NIH Grant/Contract )
P30CA023074 ( U.S. NIH Grant/Contract )
UARIZ-04-81 ( Other Identifier: CDR0000491215 )
Study First Received: May 9, 2009
Last Updated: December 2, 2015

Keywords provided by University of Arizona:
recurrent colon cancer
stage I colon cancer
stage II colon cancer
stage III colon cancer
stage IV colon cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on September 21, 2017